← Leaderboards
Veronique Belzil
Massachusetts Institute Of Technology
$4,105,202
Attributed
$12,763,565
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,763,565 · 2
By mechanism
R01$12,763,565 · 2
Top collaborators
- Manolis Kellis10 shared
- Christopher James Donnelly5 shared
- Myriam Heiman5 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Manolis Kellis$46,984,324
- Li-Huei Tsai$66,135,710
- Peter Karl Sorger$53,861,857
- Kirsten C Sadler Edepli$6,680,499
- Rudolph Emile Tanzi$37,301,297
Others in their field
Other Emerging Leaders on “Enhancers”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- John E West · University Of Texas At Austin$95,166,667
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$90,963,700
- Peter K Fritschel · California Institute Of Technology$78,820,000
Research focus
EnhancersGene Expression ProfileCrispr ScreenDistalFrontotemporal Lobar DegenerationsExperimental StudyAffectAmyotrophic Lateral SclerosisDifferential ExpressionDissectionEpigenomicsAls PatientsCandidate Disease GeneBayesian MethodBiologicalCell ModelCellsCell TypeAstrocytesData SetBrain PathologyCoculture TechniquesAutopsyGenes
Grant awards (10)
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$1,752,943
R01 · FY2025 · NS
Single-Cell Transcriptional and Epigenomic Dissection to Identify Therapeutic Targets for ALS and FTD$700,630
R01 · FY2025 · AG
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$1,818,953
R01 · FY2024 · NS
Single-Cell Transcriptional and Epigenomic Dissection to Identify Therapeutic Targets for ALS and FTD$725,002
R01 · FY2024 · AG
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$2,054,384
R01 · FY2023 · NS
Single-Cell Transcriptional and Epigenomic Dissection to Identify Therapeutic Targets for ALS and FTD$733,242
R01 · FY2023 · AG
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$1,662,271
R01 · FY2022 · NS
Single-Cell Transcriptional and Epigenomic Dissection to Identify Therapeutic Targets for ALS and FTD$741,221
R01 · FY2022 · AG
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$1,817,770
R01 · FY2021 · NS
Single-Cell Transcriptional and Epigenomic Dissection to Identify Therapeutic Targets for ALS and FTD$757,149
R01 · FY2021 · AG